Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K0706 PK and CSF Safety Study in Healthy Volunteers
NCT03445338Phase 1Completed
- Sponsor
- Sun Pharma
- Start
- Apr 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vodobatinib in Parkinson's disease (PD) (3 cohorts), sponsored by Sun Pharma. Primary endpoint: Minimum concentration of study drug in cerebrospinal fluid (CSF) at Day 8. Started Apr 2018; status: completed.
02
Drugs
vodobatinib
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03445338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03445338.